Health-related quality of life during hormone therapy after breast cancer: a randomized trial

References

• Spiegel D. Psychological aspects of breast cancer treatment. Semin Oncol 1997;24:S1-36–47
   Web of Science ®Google Scholar
• Irvine D, Brown B, Crooks D, Roberts J, Browne G. Psychosocial adjustment in women with breast cancer. Cancer 1991;67:1097–117
   PubMed Web of Science ®Google Scholar
• Nystedt M, Berglund G, Bolund C, Brandberg Y, Fornander T, Rutqvist LE. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer – self-rated physiological effects and symptoms. Acta Oncol 2000;39:959–68
   PubMed Web of Science ®Google Scholar
• Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for “well-tolerated” treatments? Breast Cancer Res Treat 2001;66:73–81
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17:2365–70
   PubMed Web of Science ®Google Scholar
• Utian WH, Archer DF, Bachmann GA, et al Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602
   PubMed Web of Science ®Google Scholar
• Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002; 23:501–9
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005;6:687–95
   PubMed Web of Science ®Google Scholar
• Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409–21
   PubMed Web of Science ®Google Scholar
• von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97:533–5
   PubMed Web of Science ®Google Scholar
• Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007;22:616–22
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–82
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76
   PubMed Web of Science ®Google Scholar
• Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact profile. Acta Oncol 1992;31:19–28
   PubMed Web of Science ®Google Scholar
• Sigurdardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters. Qual Life Res 1996;5:375–86
   PubMed Web of Science ®Google Scholar
• Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30 – reference values from a large sample of Swedish population. Acta Oncol 2000;39:477–84
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Groenvold M, Arraras JI, et al The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756–68
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70
   PubMed Web of Science ®Google Scholar
• Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77
   PubMed Web of Science ®Google Scholar
• Arving C, Glimelius B, Brandberg Y. Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale. Qual Life Res 2008;17:95–104
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A. Quality of life research within the EORTC – the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38(Suppl 4): S125–33
   PubMed Web of Science ®Google Scholar
• Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180: S312–16
   PubMed Web of Science ®Google Scholar
• MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4:58–74
   PubMedGoogle Scholar
• Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning and quality of life. J Natl Cancer Inst Monogr 2001;30:130–4
   PubMedGoogle Scholar
• Baber R, Hickey M, Kwik M. Therapy for menopausal symptoms during and after treatment for breast cancer: safety considerations. Drug Saf 2005;28:1085–100
   PubMed Web of Science ®Google Scholar
• Gainford MC, Simmons C, Nguyen H, Verma S, Clemons M. A practical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer 2005;13:573–8
   PubMed Web of Science ®Google Scholar
• Franke HR, Brood-van Zanten MM, Burger CW, van der Mooren MJ, Kenemans P. Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life. Eur J Obstet Gynecol Reprod Biol 2007;134: 143–6
   PubMed Web of Science ®Google Scholar